{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:31:44Z","timestamp":1779377504881,"version":"3.53.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.clml.2020.04.001","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T11:17:30Z","timestamp":1586776650000},"page":"e523-e528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3181","authenticated-orcid":false,"given":"Wellington F. da","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ires H.B.","family":"Massaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9534-6714","authenticated-orcid":false,"given":"Rodrigo M.","family":"Bendlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidiane I.","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira D.R.P.","family":"Velloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1567-4086","authenticated-orcid":false,"given":"Eduardo M.","family":"Rego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanderson","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.001_bib1","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.04.001_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.mayocp.2016.09.010","article-title":"Adult acute lymphoblastic leukemia","volume":"91","author":"Paul","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2020.04.001_bib3","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1080\/10428194.2017.1354372","article-title":"Advances in adult acute lymphoblastic leukemia therapy","volume":"59","author":"Aldoss","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.001_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2011-04-347872","article-title":"Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007","volume":"119","author":"Dores","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib6","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2008.18.6916","article-title":"Pediatric-inspired therapy in adults with Philadelphia chromosome\u2013negative acute lymphoblastic leukemia: the GRAALL-2003 study","volume":"27","author":"Huguet","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.001_bib7","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/leu.2017.265","article-title":"Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia","volume":"32","author":"Toft","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.04.001_bib8","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(18)30584-9","article-title":"Monitoring asparaginase activity in middle-income countries","volume":"19","author":"Cecconello","year":"2018","journal-title":"Lancet Oncol"},{"issue":"September","key":"10.1016\/j.clml.2020.04.001_bib9","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.clml.2014.06.017","article-title":"Asparaginase in acute lymphoblastic leukemia","volume":"14","author":"Kawedia","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.001_bib10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2016.7","article-title":"Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia","volume":"17","author":"Alachkar","year":"2017","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.clml.2020.04.001_bib11","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clml.2014.07.006","article-title":"Prognostic factors in adolescent and adult patients with acute lymphoblastic leukemia with two protocols of chemotherapy: a cross-sectional study","volume":"15","author":"Diogenes","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.001_bib12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.2010.32.0325","article-title":"Improved prognosis for older adolescents with acute lymphoblastic leukemia","volume":"29","author":"Pui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.001_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ajh.23886","article-title":"Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"90","author":"Kadia","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.001_bib14","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/j.clml.2018.03.001","article-title":"Treating adult acute lymphoblastic leukemia in Brazil\u2014increased early mortality using a German multicenter acute lymphoblastic leukemia-based regimen","volume":"18","author":"Fernandes da Silva Junior","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.001_bib16","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/cncr.30322","article-title":"Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: a population-based study","volume":"123","author":"Muffly","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.04.001_bib17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1182\/blood-2018-01-827949","article-title":"Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years","volume":"131","author":"Rank","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib18","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1200\/JCO.2013.50.2708","article-title":"Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia","volume":"32","author":"Douer","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.001_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.04.001_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/ajh.24419","article-title":"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-M\u00fcnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen","volume":"91","author":"Rytting","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.04.001_bib21","doi-asserted-by":"crossref","first-page":"LP-494","DOI":"10.1182\/blood.V116.21.494.494","article-title":"PEG-asparaginase intensification in adult acute lymphoblastic leukemia (ALL): significant improvement of outcome with moderate increase of liver toxicity in the German Multicenter Study Group for Adult ALL (GMALL) Study 07\/2003","volume":"116","author":"Goekbuget","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib22","first-page":"9","article-title":"Evaluation of intramuscular versus intravenous administration of l-asparaginase in childhood leukemia","volume":"1","author":"Nesbit","year":"1979","journal-title":"Am J Pediatr Hematol Oncol"},{"key":"10.1016\/j.clml.2020.04.001_bib23","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1182\/blood.V99.6.1986","article-title":"A\u00a0randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study","volume":"99","author":"Avramis","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib24","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S1470-2045(15)00363-0","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli l-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.04.001_bib25","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3109\/10428194.2014.1003056","article-title":"Asparaginase pharmacokinetics and implications of therapeutic drug monitoring","volume":"56","author":"Asselin","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.001_bib26","doi-asserted-by":"crossref","first-page":"LP-2776","DOI":"10.1182\/blood.V128.22.2776.2776","article-title":"Prevention of venous thrombotic events in adult patients with acute lymphoblastic leukemia treated in a pediatric-inspired protocol\u2014a GRAALL Study","volume":"128","author":"Orvain","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib27","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.3109\/10428194.2011.596963","article-title":"Prevention and management of asparaginase\/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel","volume":"52","author":"Stock","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.001_bib28","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s12072-019-09971-2","article-title":"Asparaginase-induced hepatotoxicity: rapid development of cholestasis and hepatic steatosis","volume":"13","author":"Kamal","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clml.2020.04.001_bib29","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A\u00a0pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.001_bib30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1080\/10428194.2019.1658099","article-title":"Asparaginase activities during intensified treatment with pegylated E coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia","volume":"61","author":"Lanvers-Kaminsky","year":"2020","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:19Z","timestamp":1761870859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S2152265020301798"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}